Drug
Ipilimumab - 3 mg/kg
Ipilimumab - 3 mg/kg is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
200%(2 trials)
Phase Distribution
Ph phase_2
2
50%
Ph phase_1
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Completed(1)
Detailed Status
Active, not recruiting1
Completed1
Recruiting1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
active_not_recruiting125%
completed125%
recruiting125%
not_yet_recruiting125%
Recent Activity
2 active trials
Showing 4 of 4
active_not_recruitingphase_2
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
NCT02648997
not_yet_recruitingphase_2
Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
NCT07689175
recruitingphase_1
A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.
NCT07134842
completedphase_1
RTA 408 Capsules in Patients With Melanoma - REVEAL
NCT02259231
Clinical Trials (4)
Showing 4 of 4 trials
NCT02648997Phase 2
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
NCT07689175Phase 2
Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
NCT07134842Phase 1
A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.
NCT02259231Phase 1
RTA 408 Capsules in Patients With Melanoma - REVEAL
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4